Fatemeh Ghadimi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fatemeh Ghadimi has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Hervette Nkwihoreze
Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania , Philadelphia, Pennsylvania
3 shared publications- Florence Momplaisir
Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
2 shared publications John B Jemmott
Department of Psychiatry, Perelman School of Medicine, and Annenberg School for Communication, University of Pennsylvania , Philadelphia, Pennsylvania
2 shared publications- Omid Dadras
Research Centre for Child Psychiatry University of Turku Turku Finland
2 shared publications - SeyedAhmad SeyedAlinaghi
Iranian Research Center for HIV/AIDS (IRCHA), Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran
2 shared publications - Aadia Rana
University of Alabama at Birmingham Heersink School of Medicine , Birmingham, Alabama
1 shared publication
Latest Publications
- Open Access
- 26 December 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (1)
Reduced Adherence to Antiretroviral Therapy in Pregnant Women With HIV With Intimate Partner Violence in the United States
Background: Despite increased access to antiretroviral therapy (ART) for women with HIV (WWH), poor postpartum HIV care retention persists. This analysis evaluates Intimate Partner Violence (IPV) and ART adherence in pregnant WWH. Methods: We analyzed secondary data from a US behavioral intervention trial to improve postpartum retention in WWH. Data were collected from the baseline survey including the Edinburgh Postnatal Depression Scale (EPDS), adverse childhood experiences (ACE), and HIV-related stigma scores, and the WHO Violence Against Women questionnaire to assess IPV. A multivariable logistic regression examined associations between IPV timing (before, during pregnancy, any) and type (physical, psychological, sexual) and ART adherence (≥80% ART doses in the prior month). Results: A total of 137 pregnant WWH enrolled between March 2020 and March 2024 were included: mean age was 30.5 (SD 5.6); 83% were Black, 14% Hispanic; mean number of pregnancies was 3.3 (SD 2.1). Depression, stigma, and ACEs were prevalent: EPDS scores of ≥10 were seen in 45% of women, ≥4 ACEs in 23%, and 51% reported HIV-related shame. Forty women (29%) reported IPV exposure. Higher EPDS, ACE, and stigma scores were seen in women exposed to IPV (P < .02). Physical IPV during pregnancy had the strongest association with decreased ART adherence in pregnancy (adjusted odds ratio = 0.10, P = .02). Psychological IPV and any IPV type during or before pregnancy were also associated with lower odds of adherence. Conclusions: We found high IPV rates and a significant negative association with ART adherence among pregnant WWH highlighting the importance of addressing IPV in HIV care.
- 26 December 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (1)
Open AccessReduced Adherence to Antiretroviral Therapy in Pregnant Women With HIV With Intimate Partner Violence in the United States
Background: Despite increased access to antiretroviral therapy (ART) for women with HIV (WWH), poor postpartum HIV care retention persists. This analysis evaluates Intimate Partner Violence (IPV) and ART adherence in pregnant WWH. Methods: We analyzed secondary data from a US behavioral intervention trial to improve postpartum retention in WWH. Data were collected from the baseline survey including the Edinburgh Postnatal Depression Scale (EPDS), adverse childhood experiences (ACE), and HIV-related stigma scores, and the WHO Violence Against Women questionnaire to assess IPV. A multivariable logistic regression examined associations between IPV timing (before, during pregnancy, any) and type (physical, psychological, sexual) and ART adherence (≥80% ART doses in the prior month). Results: A total of 137 pregnant WWH enrolled between March 2020 and March 2024 were included: mean age was 30.5 (SD 5.6); 83% were Black, 14% Hispanic; mean number of pregnancies was 3.3 (SD 2.1). Depression, stigma, and ACEs were prevalent: EPDS scores of ≥10 were seen in 45% of women, ≥4 ACEs in 23%, and 51% reported HIV-related shame. Forty women (29%) reported IPV exposure. Higher EPDS, ACE, and stigma scores were seen in women exposed to IPV (P < .02). Physical IPV during pregnancy had the strongest association with decreased ART adherence in pregnancy (adjusted odds ratio = 0.10, P = .02). Psychological IPV and any IPV type during or before pregnancy were also associated with lower odds of adherence. Conclusions: We found high IPV rates and a significant negative association with ART adherence among pregnant WWH highlighting the importance of addressing IPV in HIV care.
- Open Access
- 16 July 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (8) , ofaf417
Responding to Emerging Epidemics: Insights From Stakeholders on Mpox Vaccine Rollout in Philadelphia
Background: The 2022 mpox outbreak serves as an important example of a rapidly emerging epidemic that disproportionately affected marginalized populations. Despite the availability of a preventive vaccine, its deployment ultimately fell short of reaching the populations at greatest risk. Therefore, we sought to evaluate the vaccination campaign from the perspectives of key stakeholders. Methods: We conducted semistructured interviews to assess knowledge and perceptions of mpox, as well as barriers and facilitators to vaccine uptake in Philadelphia. We recruited health care clients and community members who were eligible for mpox vaccination and health care workers and community-based organization staff involved in vaccination efforts. We used purposeful selection to ensure inclusion of people with HIV. We used an integrated analysis approach that combined modified grounded theory and implementation science constructs. Results: We interviewed 21 health care clients, 9 community members, 10 health care workers, and 3 community-based organization staff after the primary mpox response in 2022 between February 2023 and October 2024. Participants varied in their knowledge and perceptions of mpox risk, primarily varying based on the perceived importance of sexual identity vs sexual behaviors. They generally believed that at-risk individuals should be vaccinated. Participants reported trusting mpox information from sources they trusted for other health information, such as health departments or knowledgeable members of social networks. Most participants expressed concern about inequitable distribution of the vaccine. Commonly reported facilitators to vaccination included one's own risk perception, technological literacy, co-locating vaccinations with existing clinical and social spaces, and outreach through trusted health-, community-, and social network–based resources. Knowledge, administrative (eg, difficulty signing up), and logistical (eg, limited clinic hours) barriers to vaccine access were thought to exacerbate inequities. Conclusions: While an effective mpox vaccine was a key asset in the response, barriers related to availability, accessibility, awareness, and logistical constraints limited its reach to those at highest risk.
- 16 July 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (8) , ofaf417
Open AccessResponding to Emerging Epidemics: Insights From Stakeholders on Mpox Vaccine Rollout in Philadelphia
Background: The 2022 mpox outbreak serves as an important example of a rapidly emerging epidemic that disproportionately affected marginalized populations. Despite the availability of a preventive vaccine, its deployment ultimately fell short of reaching the populations at greatest risk. Therefore, we sought to evaluate the vaccination campaign from the perspectives of key stakeholders. Methods: We conducted semistructured interviews to assess knowledge and perceptions of mpox, as well as barriers and facilitators to vaccine uptake in Philadelphia. We recruited health care clients and community members who were eligible for mpox vaccination and health care workers and community-based organization staff involved in vaccination efforts. We used purposeful selection to ensure inclusion of people with HIV. We used an integrated analysis approach that combined modified grounded theory and implementation science constructs. Results: We interviewed 21 health care clients, 9 community members, 10 health care workers, and 3 community-based organization staff after the primary mpox response in 2022 between February 2023 and October 2024. Participants varied in their knowledge and perceptions of mpox risk, primarily varying based on the perceived importance of sexual identity vs sexual behaviors. They generally believed that at-risk individuals should be vaccinated. Participants reported trusting mpox information from sources they trusted for other health information, such as health departments or knowledgeable members of social networks. Most participants expressed concern about inequitable distribution of the vaccine. Commonly reported facilitators to vaccination included one's own risk perception, technological literacy, co-locating vaccinations with existing clinical and social spaces, and outreach through trusted health-, community-, and social network–based resources. Knowledge, administrative (eg, difficulty signing up), and logistical (eg, limited clinic hours) barriers to vaccine access were thought to exacerbate inequities. Conclusions: While an effective mpox vaccine was a key asset in the response, barriers related to availability, accessibility, awareness, and logistical constraints limited its reach to those at highest risk.
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
2393. Factors Associated with Time to COVID-19 Vaccination among People with HIV
The COVID-19 pandemic has significantly impacted at-risk populations, including people with HIV/AIDS (PWHA). Several reports indicate a higher risk of SARS-CoV-2 infection and mortality in PWHA compared to the general population. Despite an effective vaccine, PWHA with low CD4 count develop a weak immune response and are at risk of severe breakthrough infections. Vaccination gaps have been identified amongst PWHA, but factors associated with time to mRNA COVID-19 vaccine initiation and first booster have not been studied. PWHA age ≥ 18 years, in HIV care at an urban clinic, and who completed the primary series of COVID-19 vaccines were invited to complete an online survey. Socio-demographic and clinical characteristics and COVID-19 vaccination motivators were assessed and complemented by a review of medical records. Statements on motivators to vaccination were rated on a 5-point Likert scale treated as ordinal data (minimum score 19, maximum 95). Factors associated with time to first COVID-19 vaccine and first booster were analyzed by the Kaplan-Meier method. A total of 129 patients enrolled; 83% (108/129) received the COVID-19 booster. Mean age was 50.3 (±10.9) years; 26.4% were female; 54.3% were Black, and 34.1% were White; 91.5% were non-Hispanic. The mean nadir CD4 count throughout their care was 309.4 (±245.6) cells/mm3. The mean time to first COVID-19 vaccine dose was 2.8 (±1.8) months from December 2020 (Pfizer-BioNTech vaccine approval), and time to first booster was 9.9 (±3.8) months from the date of the first vaccine. Factors associated with quicker uptake of the first dose included being ≥ 51 years of age (p=0.001), White race (p=0.027), male sex (p=0.023), and gay/lesbian identity (p=0.014) (Fig 1). Factors associated with quicker uptake of the first booster included being ≥ 51 years of age (p < 0.000) and a COVID-19 motivators’ survey score > 69 (p=0.017) (Fig 2). Kaplan-Meier Curves for Time to COVID-19 First Dose Vaccination Among People Living with HIV/AIDS Receiving HIV Care through Penn Medicine. Kaplan-Meier Curves for Time to COVID-19 First Booster Vaccination Among People Living with HIV/AIDS Receiving HIV Care through Penn Medicine. We found high rates of COVID-19 booster vaccination among PWHA. White and male patients got vaccinated quicker in the early phase of the pandemic; however, race and age-based inequities resolved in the later phase of the pandemic. Motivation to vaccination emerged as a facilitator for uptake of booster vaccines. All Authors: No reported disclosures
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access2393. Factors Associated with Time to COVID-19 Vaccination among People with HIV
The COVID-19 pandemic has significantly impacted at-risk populations, including people with HIV/AIDS (PWHA). Several reports indicate a higher risk of SARS-CoV-2 infection and mortality in PWHA compared to the general population. Despite an effective vaccine, PWHA with low CD4 count develop a weak immune response and are at risk of severe breakthrough infections. Vaccination gaps have been identified amongst PWHA, but factors associated with time to mRNA COVID-19 vaccine initiation and first booster have not been studied. PWHA age ≥ 18 years, in HIV care at an urban clinic, and who completed the primary series of COVID-19 vaccines were invited to complete an online survey. Socio-demographic and clinical characteristics and COVID-19 vaccination motivators were assessed and complemented by a review of medical records. Statements on motivators to vaccination were rated on a 5-point Likert scale treated as ordinal data (minimum score 19, maximum 95). Factors associated with time to first COVID-19 vaccine and first booster were analyzed by the Kaplan-Meier method. A total of 129 patients enrolled; 83% (108/129) received the COVID-19 booster. Mean age was 50.3 (±10.9) years; 26.4% were female; 54.3% were Black, and 34.1% were White; 91.5% were non-Hispanic. The mean nadir CD4 count throughout their care was 309.4 (±245.6) cells/mm3. The mean time to first COVID-19 vaccine dose was 2.8 (±1.8) months from December 2020 (Pfizer-BioNTech vaccine approval), and time to first booster was 9.9 (±3.8) months from the date of the first vaccine. Factors associated with quicker uptake of the first dose included being ≥ 51 years of age (p=0.001), White race (p=0.027), male sex (p=0.023), and gay/lesbian identity (p=0.014) (Fig 1). Factors associated with quicker uptake of the first booster included being ≥ 51 years of age (p < 0.000) and a COVID-19 motivators’ survey score > 69 (p=0.017) (Fig 2). Kaplan-Meier Curves for Time to COVID-19 First Dose Vaccination Among People Living with HIV/AIDS Receiving HIV Care through Penn Medicine. Kaplan-Meier Curves for Time to COVID-19 First Booster Vaccination Among People Living with HIV/AIDS Receiving HIV Care through Penn Medicine. We found high rates of COVID-19 booster vaccination among PWHA. White and male patients got vaccinated quicker in the early phase of the pandemic; however, race and age-based inequities resolved in the later phase of the pandemic. Motivation to vaccination emerged as a facilitator for uptake of booster vaccines. All Authors: No reported disclosures
- 1 May 2021
- Published by Bentham Science Publishers Ltd. in Infectious Disorders - Drug Targets
- Vol. 21 (3) , 394-398
Bone Marrow Aspiration/Biopsy in the Evaluation of Fever of Unknown Origin in Patients with AIDS
Background: HIV can interrupt the normal development of bone marrow cell lines. Bone marrow aspiration/biopsy (BMA/B) has been described as a diagnostic tool in AIDS patients with fever of unknown origin (FUO). In this review, we aimed to study patients with AIDS who had undergone a BMA/B to investigate FUO and describe the pathologies diagnosed in the biopsy. Methods: Thirty-four BMA/B samples were collected from AIDS patients admitted for work-up of FUO to the infectious disease ward of a tertiary referral HIV center in Tehran, Iran, between September 2014 and September 2015. Data including age, sex, duration of disease, CD4 cell counts, hepatitis B (HBV) and C (HCV) coinfection, the primary presentation of AIDS, and the treatment history were retrieved and analyzed. Patients underwent BMA/B. An expert pathologist reviewed the BMA/B specimens. Results: The mean age of the patients was 37.5 years (range, 26-56), and 27 (79%) were men. Twenty-seven (79%) patients contracted HIV from injection drug use, and 7 (21%) via sexual transmission. Only 3 (9%) of the BMA/B examinations were normal. Hypocellular bone marrow was diagnosed in 22 (65%) patients. Other pathologies included granulomas in 6 (18%), hematologic malignancies in 2 (6%), and leishmaniasis Aspergillosis, each in 1 (3%) patient. Six (17%) of the specimens were found to have tuberculosis infections. Conclusion: Hypocellular bone marrow was the most common pathology on BMA/B examinations, followed by the presence of granulomas. Tuberculosis, Aspergillosis, and Leishmaniasis the opportunistic infections diagnosed on BMA/B specimens. Our results support BMA/B as an appropriate diagnostic tool for early diagnosis of opportunistic infections and malignancies in AIDS. BMA/B is indispensable in the armament of diagnostic tools of the physicians managing AIDS patients.
- 1 May 2021
- Published by Bentham Science Publishers Ltd. in Infectious Disorders - Drug Targets
- Vol. 21 (3) , 394-398
Bone Marrow Aspiration/Biopsy in the Evaluation of Fever of Unknown Origin in Patients with AIDS
Background: HIV can interrupt the normal development of bone marrow cell lines. Bone marrow aspiration/biopsy (BMA/B) has been described as a diagnostic tool in AIDS patients with fever of unknown origin (FUO). In this review, we aimed to study patients with AIDS who had undergone a BMA/B to investigate FUO and describe the pathologies diagnosed in the biopsy. Methods: Thirty-four BMA/B samples were collected from AIDS patients admitted for work-up of FUO to the infectious disease ward of a tertiary referral HIV center in Tehran, Iran, between September 2014 and September 2015. Data including age, sex, duration of disease, CD4 cell counts, hepatitis B (HBV) and C (HCV) coinfection, the primary presentation of AIDS, and the treatment history were retrieved and analyzed. Patients underwent BMA/B. An expert pathologist reviewed the BMA/B specimens. Results: The mean age of the patients was 37.5 years (range, 26-56), and 27 (79%) were men. Twenty-seven (79%) patients contracted HIV from injection drug use, and 7 (21%) via sexual transmission. Only 3 (9%) of the BMA/B examinations were normal. Hypocellular bone marrow was diagnosed in 22 (65%) patients. Other pathologies included granulomas in 6 (18%), hematologic malignancies in 2 (6%), and leishmaniasis Aspergillosis, each in 1 (3%) patient. Six (17%) of the specimens were found to have tuberculosis infections. Conclusion: Hypocellular bone marrow was the most common pathology on BMA/B examinations, followed by the presence of granulomas. Tuberculosis, Aspergillosis, and Leishmaniasis the opportunistic infections diagnosed on BMA/B specimens. Our results support BMA/B as an appropriate diagnostic tool for early diagnosis of opportunistic infections and malignancies in AIDS. BMA/B is indispensable in the armament of diagnostic tools of the physicians managing AIDS patients.
- 8 September 2020
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 18 (4) , 228-236
Epidemiology of HIV in Iran
Iran has been one the active countries fighting against HIV/AIDS in Middle East during last decades. Moreover, there is a strong push to strengthen the national health management system concerning HIV prevention and control. In Iran, HIV disease has its own unique features, from changes in modes of transmission to improvement in prevention programs, which can make it a good case for closer scrutiny. The present review describes the HIV epidemic in Iran from the first case diagnosed till recent progresses in diagnosis, treatment, and prevention among different groups at risk. Not only we addressed the key populations and community-based attempts to overcome HIV-related issues in clinics, but we also elaborated on the efforts and trends in society and the actual behaviors related to HIV/AIDS. Being located in the Middle East and North Africa (MENA) region, given the country-specific characteristics, despite all the national efforts along with other countries in this region, Iran still needs to take extra measures to reduce HIV transmission, especially in health education. Although Iran is one of the pioneers in implementing pertinent policies in the MENA region, including harm reduction services to reduce HIV incidence, people with substance use disorder continue to be the majority of those living with HIV in the country. Similar to other countries in this region, the HIV prevention and control programs aim at 90-90-90 targets to eliminate HIV infection and reduce the transmission, especially the mother-to-child transmission and among other key populations.
- 8 September 2020
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 18 (4) , 228-236
Epidemiology of HIV in Iran
Iran has been one the active countries fighting against HIV/AIDS in Middle East during last decades. Moreover, there is a strong push to strengthen the national health management system concerning HIV prevention and control. In Iran, HIV disease has its own unique features, from changes in modes of transmission to improvement in prevention programs, which can make it a good case for closer scrutiny. The present review describes the HIV epidemic in Iran from the first case diagnosed till recent progresses in diagnosis, treatment, and prevention among different groups at risk. Not only we addressed the key populations and community-based attempts to overcome HIV-related issues in clinics, but we also elaborated on the efforts and trends in society and the actual behaviors related to HIV/AIDS. Being located in the Middle East and North Africa (MENA) region, given the country-specific characteristics, despite all the national efforts along with other countries in this region, Iran still needs to take extra measures to reduce HIV transmission, especially in health education. Although Iran is one of the pioneers in implementing pertinent policies in the MENA region, including harm reduction services to reduce HIV incidence, people with substance use disorder continue to be the majority of those living with HIV in the country. Similar to other countries in this region, the HIV prevention and control programs aim at 90-90-90 targets to eliminate HIV infection and reduce the transmission, especially the mother-to-child transmission and among other key populations.